KI’s new President: “We need to work closer together”

A closer link between research and education and a stronger “we-feeling” are aims that Annika Östman Wernerson sets out to achieve as the new President of Karolinska Institutet. She will not give up her research entirely though. “I think it’s crucial to maintain a close presence in the business,” she says.

Major advances in IVF labs in the last few decades

Since the introduction of in vitro fertilisation several decades ago, many developments have been made in the field, and the main part of that development has taken place in the lab.

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writes in an editorial.

Rapid development in blood analysis – “Sweden is leading the race”

Thousands of analytical tests using just one single drop of blood. What was revealed as a hoax just a few years ago is now a reality, according to KTH professor and serial entrepreneur Mathias Uhlén.

Column: ”Authentic leadership and clear mandates pave the way for more female CEOs”

”I believe that the aspect of having clear mandates and titles on the one hand and women progressing into top positions must be explored further”, Helena Strigård writes in a column.

Precision medicine centre: “Extensive activity on several fronts”

Two years ago, the Karolinska Institutet and the Karolinska University Hospital announced that they would jointly launch the Precision Medicine Centre. Medtech Magazine called Anna Wedell, who is heading the work, to find out…

Column: ”We need to exploit the benefits of the regulations“

You don’t need to search long on the Internet to find lists of the most innovative countries with Sweden ranking at the top. Sweden generally offers good conditions for growing new solutions, but it is also becoming increasingly clear that we are challenged in one area – regulations, writes Björn Arvidsson in a column.

The new Astra Zeneca CEO: “An incredibly exciting phase”

Almost 27 years have passed since Per Alfredsson from Södertälje stepped into Astra Zeneca as a newly hired engineer. After countless different roles, including heading the production of the company’s Covid vaccine, he is now advancing to the absolute top.

She creates pharmaceuticals on a 3D printer

The correct dosage for each individual, regardless of whether the pharmaceutical is for a seriously ill child or a frail elderly person, is the mission of a well-advanced project with 3D-printed drugs at Uppsala University. “It will soon be available in clinics”, says Christel Bergström, who is heading the project.

Outsourcing som strategi för ökad trovärdighet

Idag, torsdag, pågår Life Science Swedens event Pharma Outsourcing på Stockholm Waterfront. Under en av föreläsningarna jämfördes för- och nackdelar med att ta sig an uppgifter och problem internt med att köpa in tjänster.

Dags för ”ett av våra mest efterfrågade möten”

The stomach medication that became the biggest blockbuster of the 1990s

The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tablet was available that was soon to help millions of people worldwide and break all sales records.

Magmedicinen som blev 90-talets största blockbuster

Redan 1979 syntetiserades omeprazolmolekylen. Men det kom att dröja många år innan dåvarande Astra hade ett godkänt läkemedel. När det väl skedde fanns en tablett som kom att hjälpa miljontals människor i världen – och slå alla försäljningsrekord.

He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new GMP facility.

Flyttar gränser för gen- och cellterapi

”Vi är bra på att vara innovativa och flytta gränser inom gen- och cellterapi och den här studien symboliserar det på ett tydligt sätt”, säger Evelina Vågesjö, vd för Ilya Pharma, om den kliniska studie som företaget startar nästa år.

Han går på djupet med topikala beredningar

Topikala produkter inom läkemedelsutveckling är en växande marknad, enligt Zelmics vd David Sagna, och för att hålla jämna steg med utvecklingen väntar företaget på godkännande för sin nya GMP-anläggning.

Swedish breakthrough in Alzheimer’s: “We can finally present great data”

Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.

"Are we doing business the wrong way around in the Life Science Sector?"

For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which were great for that time but now we realise that these drugs were in fact only tested in white men and certainly not for patients who are older who are taking a number of medications.

Svenskt genombrott inom Alzheimers i fokus på Bioscience: "Äntligen har vi fina data"

Behandlingar mot Alzheimers sjukdom hör till det hetaste just nu inom läkemedelsutveckling. Två svenska forskningsbolag med stora ambitioner – och framgångar – inom området deltog vid tisdagens konferens Bioscience 2022 på Life City i Hagastaden.

”Dags för vårdens beslutsfattare att laga efter läge, snarare än att lappa och laga”

Problemen i vården framstår alltmer som en gordisk knut, och precis som i myten om Alexander den store kanske även dessa problem är mer lättlösta än vad man tror, skriver Petter Hartman i en krönika.

Lucy Robertshaw startar mötesplats om svensk life science

Lucy Robertshaw, som modererat flera event åt Life Science Sweden, lanserar en sajt på engelska om svensk life science.

“We need to build flexible operating theatres”

Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas that three specialist surgeons are suggesting for the operating theatre of the future.

“We aim to be a start-up company with an academic spirit”

Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working on developing drugs for both conditions.

”Riktlinjer följs inte alltid som man skulle önska”

Det behövs kontaktytor mellan vårdprofession, patienter och företag, konstaterar Penilla Gunther och Mattias Hellström i en tv-intervju från Fokus Patient Event.